---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-14T17:16:00.287670'
end_time: '2025-12-14T17:22:21.682517'
duration_seconds: 381.39
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: PLD3
  gene_symbol: PLD3
  uniprot_accession: Q8IV08
  protein_description: 'RecName: Full=5''-3'' exonuclease PLD3 {ECO:0000305}; EC=3.1.16.1
    {ECO:0000269|PubMed:30111894, ECO:0000269|PubMed:30312375}; AltName: Full=(S,S)-bis(monoacylglycero)phosphate
    synthase PLD3 {ECO:0000305|PubMed:39423811}; EC=3.1.4.- {ECO:0000269|PubMed:39423811};
    AltName: Full=HindIII K4L homolog; AltName: Full=Hu-K4 {ECO:0000303|PubMed:15794758};
    AltName: Full=Phospholipase D3;'
  gene_info: Name=PLD3 {ECO:0000303|PubMed:26411346, ECO:0000312|HGNC:HGNC:17158};
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the phospholipase D family. .
  protein_domains: Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase.
    (IPR001736); PLDc_3 (PF13918)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 25
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8IV08
- **Protein Description:** RecName: Full=5'-3' exonuclease PLD3 {ECO:0000305}; EC=3.1.16.1 {ECO:0000269|PubMed:30111894, ECO:0000269|PubMed:30312375}; AltName: Full=(S,S)-bis(monoacylglycero)phosphate synthase PLD3 {ECO:0000305|PubMed:39423811}; EC=3.1.4.- {ECO:0000269|PubMed:39423811}; AltName: Full=HindIII K4L homolog; AltName: Full=Hu-K4 {ECO:0000303|PubMed:15794758}; AltName: Full=Phospholipase D3;
- **Gene Information:** Name=PLD3 {ECO:0000303|PubMed:26411346, ECO:0000312|HGNC:HGNC:17158};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the phospholipase D family. .
- **Key Domains:** Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase. (IPR001736); PLDc_3 (PF13918)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "PLD3" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'PLD3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **PLD3** (gene ID: PLD3, UniProt: Q8IV08) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8IV08
- **Protein Description:** RecName: Full=5'-3' exonuclease PLD3 {ECO:0000305}; EC=3.1.16.1 {ECO:0000269|PubMed:30111894, ECO:0000269|PubMed:30312375}; AltName: Full=(S,S)-bis(monoacylglycero)phosphate synthase PLD3 {ECO:0000305|PubMed:39423811}; EC=3.1.4.- {ECO:0000269|PubMed:39423811}; AltName: Full=HindIII K4L homolog; AltName: Full=Hu-K4 {ECO:0000303|PubMed:15794758}; AltName: Full=Phospholipase D3;
- **Gene Information:** Name=PLD3 {ECO:0000303|PubMed:26411346, ECO:0000312|HGNC:HGNC:17158};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the phospholipase D family. .
- **Key Domains:** Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase. (IPR001736); PLDc_3 (PF13918)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "PLD3" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'PLD3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **PLD3** (gene ID: PLD3, UniProt: Q8IV08) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research report: Human PLD3 (UniProt Q8IV08)

Identity verification and core definitions
- Gene/protein identity: PLD3 encodes phospholipase D3, a type II single-pass transmembrane glycoprotein localized to the endolysosomal system in human cells. The luminal domain contains the conserved PLD/PLDc (HKD) catalytic motifs characteristic of the phospholipase D superfamily, consistent with UniProt Q8IV08 annotations and “Diverse_PLD-related” domain membership (Homo sapiens). Structural work on human PLD3 confirms the PLD fold and active site architecture in the luminal domain (N-glycosylated), supporting assignment to the PLD family (published Nov 22, 2023; Nucleic Acids Research 2024; URL: https://doi.org/10.1093/nar/gkad1114) (roske2024structuralanalysisof pages 1-2). Complementary structural/biochemical analyses (Structure, Jun 2024; URL: https://doi.org/10.1016/j.str.2024.02.019) demonstrate PLD3 as an endolysosomal 5′ exonuclease with catalysis driven by the HKD histidine, aligning family/domain expectations (yuan2024structuralandmechanistic pages 14-17).

- Primary biochemical activities: Two activities have been reported for human PLD3.
  1) Lysosomal 5′→3′ exonuclease on nucleic acids: Multiple studies show PLD3 cleaves ssDNA and ssRNA from the 5′ end at acidic pH consistent with the lysosome; loss of PLD3 slows luminal nucleic-acid degradation and can potentiate nucleic-acid–sensing pathways (JBC, Jan 2021; URL: https://doi.org/10.1074/jbc.ra120.015867; NAR 2024; Structure 2024) (cappel2021quantificationandcharacterization pages 1-2, roske2024structuralanalysisof pages 1-2, yuan2024structuralandmechanistic pages 14-17).
  2) BMP synthase activity: A 2024 Cell study reports purified PLD3 (and paralog PLD4) synthesize the S,S stereoisomer of bis(monoacylglycero)phosphate (S,S‑BMP) via a transphosphatidylation reaction in lysosomal contexts; PLD3 loss reduces cellular BMP and perturbs lysosomal lipid catabolism (Cell, Nov 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).

- Topology, maturation, and modification: PLD3 is synthesized as a type II transmembrane protein and undergoes proteolytic cleavage in lysosomes to generate a soluble luminal enzyme that is catalytically active; dimerization of luminal domains creates two catalytic centers per dimer (NAR 2024; URL: https://doi.org/10.1093/nar/gkad1114) (roske2024structuralanalysisof pages 1-2). A recent preprint indicates PLD3’s soluble form can be AMPylated during neuronal maturation; mapped AMPylation sites modulate processing and activity (bioRxiv, Jan 2025; URL: https://doi.org/10.1101/2025.01.09.632087) (hoffmann2025ampylationregulatespld3 pages 1-3, hoffmann2025ampylationregulatespld3 pages 26-27).

Current understanding: functions, substrates, reactions
- 5′ exonuclease function and substrates: PLD3 preferentially degrades short single-stranded nucleic acids in the lysosomal lumen with an acidic pH optimum around ~6.0; Mg2+/Ca2+ can stimulate activity, and vanadate inhibits activity (IC50 ~10 µM in lysates). A dedicated cell-based assay demonstrated PLD3 as the principal acid 5′ exonuclease in HeLa cells; proteolytic processing is not strictly required for hydrolytic activity in cells (JBC 2021; URL: https://doi.org/10.1074/jbc.ra120.015867) (cappel2021quantificationandcharacterization pages 6-7, cappel2021quantificationandcharacterization pages 1-2). Structural snapshots with bound thymidine product delineate substrate binding and a mechanism consistent with PLD-family catalysis (NAR 2024; URL: https://doi.org/10.1093/nar/gkad1114) (roske2024structuralanalysisof pages 1-2). PLD3 targets include mitochondrial DNA fragments delivered to lysosomes via mitophagy; PLD3 deficiency leads to lysosomal mtDNA accumulation (Nat Commun, May 2023; URL: https://doi.org/10.1038/s41467-023-38501-w) (acker2023phospholipased3degrades pages 9-12).

- S,S‑BMP synthase function and substrates: PLD3 catalyzes S,S‑BMP formation in vitro and in cells, supporting lysosomal lipid degradation. In cells and tissues, PLD3 loss reduces BMP and increases lysosomal cholesterol and gangliosides; exogenous S,S‑BMP can rescue multiple phenotypes, implicating PLD3-dependent BMP in lysosomal lipid homeostasis (Cell 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).

Subcellular localization and processing
- Localization: PLD3 localizes to neurons and is enriched in lysosomes/dystrophic neurites around β‑amyloid plaques in AD brain; neuronal PLD3 co-localizes with LAMP2 and cathepsins (PLoS Genetics, Aug 2021; URL: https://doi.org/10.1101/746222) (nackenoff2021pld3isa pages 4-6). PLD3 is a type II transmembrane protein whose luminal domain is proteolytically released to form the active soluble lysosomal enzyme (NAR 2024; URL: https://doi.org/10.1093/nar/gkad1114) (roske2024structuralanalysisof pages 1-2). Preprint data indicate AMPylation of the soluble lysosomal form during neuronal differentiation influences its processing/activity (bioRxiv 2025; URL: https://doi.org/10.1101/2025.01.09.632087) (hoffmann2025ampylationregulatespld3 pages 1-3, hoffmann2025ampylationregulatespld3 pages 26-27).

Pathway context
- Lysosomal nucleic acid catabolism and innate immune signaling: By degrading ssDNA/ssRNA, PLD3 limits activation of endolysosomal nucleic-acid sensors (TLR9/TLR7). In PLD3 deficiency, luminal nucleic acids accumulate and can chronically activate TLRs; leakage of mtDNA into cytosol activates cGAS–STING signaling, driving autophagy, APP-CTF elevation, and cholesterol biosynthesis changes (NAR 2024; URL: https://doi.org/10.1093/nar/gkad1114; Nat Commun 2023; URL: https://doi.org/10.1038/s41467-023-38501-w) (roske2024structuralanalysisof pages 1-2, acker2023phospholipased3degrades pages 9-12).
- Lysosomal lipid metabolism and BMP biogenesis: PLD3 synthesizes S,S‑BMP to support lipid catabolism on intralumenal vesicles; PLD3 loss reduces BMP, increases lysosomal cholesterol, and induces membrane damage signatures (galectin‑3 recruitment); many defects are rescued by exogenous S,S‑BMP, linking key neuronal phenotypes to BMP deficiency (Cell 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).
- Lysosomal biogenesis and TFEB/TFE3: Preprint evidence suggests PLD3 regulates TFEB/TFE3 protein turnover via proteasome-mediated degradation, such that PLD3 loss elevates TFEB/TFE3 protein levels and nuclear translocation, amplifying lysosomal biogenesis programs; Aβ exposure augments these changes, consistent with endolysosomal stress (bioRxiv, Sep 2024; URL: https://doi.org/10.1101/2024.09.26.615214) (wang2024phospholipased3regulates pages 1-4, wang2024phospholipased3regulates pages 4-7, wang2024phospholipased3regulates pages 10-12, wang2024phospholipased3regulates pages 24-27, wang2024phospholipased3regulates pages 27-30).

Recent developments and late-breaking evidence (2023–2024 priority)
- Structural mechanism of nucleic-acid cleavage: Two independent structural studies in 2024 delineate PLD3’s luminal architecture, dimerization, and product-bound active site, confirming 5′ exonuclease function and informing the impact of disease-associated variants (Structure, Jun 2024; URL: https://doi.org/10.1016/j.str.2024.02.019; NAR, Nov 2024; URL: https://doi.org/10.1093/nar/gkad1114) (yuan2024structuralandmechanistic pages 14-17, roske2024structuralanalysisof pages 1-2).
- Lysosomal lipid biology: A 2024 Cell study redefines PLD3 as a BMP synthase; neuronal PLD3 loss causes ~70% reduction of BMP in brain with ganglioside accrual; PLD3-deficient cells show ~1.5-fold lysosomal cholesterol increase without changing total cellular cholesterol. S,S‑BMP supplementation reverses lysosomal dysfunction (Cell, Nov 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).
- Nucleotide signaling/AD pathways: 2023 work demonstrates PLD3 degrades lysosomal mtDNA; PLD3 deficiency activates cGAS–STING and elevates APP‑CTF, linking lysosomal nucleotide metabolism to AD-relevant proteostasis and lipid remodeling. Pharmacologic STING inhibition rescues APP‑CTF (Nat Commun, May 2023; URL: https://doi.org/10.1038/s41467-023-38501-w) (acker2023phospholipased3degrades pages 9-12).
- Lysosomal biogenesis control: Preprint (2024) implicates PLD3 in TFEB/TFE3 proteostasis: PLD3 loss increases TFEB/TFE3 protein (not mRNA) and nuclear activity, in line with broader lysosomal remodeling seen upon PLD3 deficiency (bioRxiv, Sep 2024; URL: https://doi.org/10.1101/2024.09.26.615214) (wang2024phospholipased3regulates pages 1-4, wang2024phospholipased3regulates pages 4-7, wang2024phospholipased3regulates pages 10-12, wang2024phospholipased3regulates pages 24-27, wang2024phospholipased3regulates pages 27-30).

Disease relevance: Alzheimer’s disease and neurodegeneration
- Genetics/neuropathology: PLD3 variants (e.g., V232M) have been associated with AD risk in some cohorts; in brain tissue, PLD3 is enriched in neuronal lysosomes and dystrophic neurites surrounding plaques, with expression inversely correlated with amyloid burden and cognitive decline. PLD3 activity was detected in isolated lysosomes and was reduced by AD‑associated mutations (PLoS Genetics preprint version, Aug 2021; URL: https://doi.org/10.1101/746222) (nackenoff2021pld3isa pages 4-6).
- Axonal spheroids and network dysfunction: In vivo imaging in AD-model mice shows plaque-associated axonal spheroids (PAASs) act as current sinks causing conduction block. Neuronal Pld3 overexpression enlarged spheroids and worsened conduction; Pld3 deletion reduced endolysosomal vesicles/spheroid size and improved network function, indicating PLD3 as a modulator of neuronal endolysosomal biogenesis and circuit physiology (Nature, Nov 2022; URL: https://doi.org/10.1038/s41586-022-05491-6) (yuan2022pld3affectsaxonal pages 1-2).
- APP-CTF and cholesterol homeostasis via cGAS–STING: PLD3 deficiency causes lysosomal mtDNA accumulation and leakage that activates cGAS–STING, which in turn increases APP‑CTF and alters cholesterol biosynthesis. STING inhibition normalized APP‑CTF, and APP deletion reduced STING activation, demonstrating bidirectional crosstalk (Nat Commun, May 2023; URL: https://doi.org/10.1038/s41467-023-38501-w) (acker2023phospholipased3degrades pages 9-12).

Current applications and real-world implementations
- Mechanistic biomarkers and target engagement: The JBC assay for acidic 5′ exonuclease activity provides a cell-based readout of PLD3/PLD4 function and inhibitor profiling (JBC, Jan 2021; URL: https://doi.org/10.1074/jbc.ra120.015867) (cappel2021quantificationandcharacterization pages 1-2, cappel2021quantificationandcharacterization pages 6-7).
- Therapeutic concepts:
  • Modulating innate immune signaling: cGAS–STING inhibitors normalized APP‑CTF in PLD3-deficient models, suggesting a route to mitigate downstream pathology from lysosomal nucleotide accumulation (Nat Commun 2023; URL: https://doi.org/10.1038/s41467-023-38501-w) (acker2023phospholipased3degrades pages 9-12).
  • Restoring BMP: Exogenous S,S‑BMP rescued cholesterol accumulation and lysosomal dysfunction in PLD3-deficient cells, nominating BMP supplementation or enhancing endogenous BMP synthesis as a strategy (Cell 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).
  • Lysosomal biogenesis tuning: Preclinical data suggest PLD3 influences TFEB/TFE3-driven lysosomal programs; modulating this axis may correct endolysosomal stress in neurons (bioRxiv 2024; URL: https://doi.org/10.1101/2024.09.26.615214) (wang2024phospholipased3regulates pages 1-4, wang2024phospholipased3regulates pages 4-7, wang2024phospholipased3regulates pages 10-12, wang2024phospholipased3regulates pages 24-27, wang2024phospholipased3regulates pages 27-30).

Expert opinions and authoritative analyses
- Structural/mechanistic reviews and perspectives in 2024 independently converge that PLD3 is a lysosomal 5′ exonuclease structurally adapted for ssNA binding and cleavage, with disease variants impairing stability/activity (Structure 2024; URL: https://doi.org/10.1016/j.str.2024.02.019; NAR 2024; URL: https://doi.org/10.1093/nar/gkad1114) (yuan2024structuralandmechanistic pages 14-17, roske2024structuralanalysisof pages 1-2).
- The 2024 Cell study reframes PLD3/PLD4 as BMP synthases essential for lysosomal lipid catabolism, providing a unifying model wherein PLD3 couples nucleic-acid clearance and lipid homeostasis via BMP (Cell 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).

Key statistics and quantitative data (selected)
- Enzymology (cell-based): pH optimum ~6.0 for PLD3 5′ exonuclease; vanadate IC50 ~10 µM in lysates; EDTA increases activity (~1.4× in lysate; ~5× for recombinant protein); PLD3 shows higher specific acidic 5′ exonuclease activity than PLD4 in HeLa cells (JBC 2021; URL: https://doi.org/10.1074/jbc.ra120.015867) (cappel2021quantificationandcharacterization pages 6-7, cappel2021quantificationandcharacterization pages 1-2).
- Lipidomics/lysosomal metrics: PLD3 loss causes ~70% reduction of BMP in mouse brain, increased lysosomal cholesterol (~1.5×), increased galectin‑3–positive damage, and ganglioside accumulation; exogenous S,S‑BMP reverses phenotypes (Cell 2024; URL: https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8).
- Innate signaling and proteostasis: In PLD3-defective cells, cGAS–STING activation elevates APP‑CTF; STING inhibitor H‑151 reduced APP‑CTF; APP knockout reduced STING activation (Nat Commun 2023; URL: https://doi.org/10.1038/s41467-023-38501-w) (acker2023phospholipased3degrades pages 9-12).
- Neuronal physiology: In AD-model mice, spheroid size correlates with conduction blockade severity; Pld3 deletion reduced endolysosomal vesicle load and spheroid size and improved conduction/network function, while Pld3 overexpression worsened both (Nature 2022; URL: https://doi.org/10.1038/s41586-022-05491-6) (yuan2022pld3affectsaxonal pages 1-2).

Synthesis and current model
- PLD3 is a human lysosomal protein whose luminal domain, released by proteolysis, acts as a 5′→3′ exonuclease on ssDNA/ssRNA and, per 2024 evidence, also catalyzes S,S‑BMP synthesis central to lysosomal lipid catabolism. These functions position PLD3 at the intersection of lysosomal nucleic-acid clearance (limiting TLR7/9 and cGAS–STING activation) and lipid homeostasis (BMP-dependent degradation of lipids and cholesterol mobilization). In neurons, PLD3 levels/activity modulate endolysosomal vesicle burden, axonal spheroid formation, and network conduction. Loss or dysfunction of PLD3 perturbs lysosomal catabolism (nucleic acids and lipids), triggers innate signaling cascades, alters APP‑CTF and cholesterol handling, and elicits compensatory lysosomal biogenesis via TFEB/TFE3—mechanistic axes highly relevant to Alzheimer’s disease pathogenesis (Structure 2024; NAR 2024; Cell 2024; Nat Commun 2023; PLoS Genetics 2021) (yuan2024structuralandmechanistic pages 14-17, roske2024structuralanalysisof pages 1-2, singh2024pld3andpld4 pages 7-8, acker2023phospholipased3degrades pages 9-12, nackenoff2021pld3isa pages 4-6).

Notes on data strength and open questions
- The 5′ exonuclease role is strongly supported by structural biochemistry (2024) and prior enzymology (2021). The BMP synthase role is supported by orthogonal lipid biochemistry/cell and mouse data in Cell (2024). Reconciling dual activities—conditions, regulation, and substrate competition—remains an active area; exogenous S,S‑BMP rescuing mtDNA-related phenotypes argues BMP deficiency is a dominant driver in some contexts (Cell 2024) (singh2024pld3andpld4 pages 7-8). The TFEB/TFE3 regulatory role and AMPylation control are emerging from preprints and warrant peer‑reviewed confirmation (bioRxiv 2024/2025) (wang2024phospholipased3regulates pages 1-4, wang2024phospholipased3regulates pages 4-7, wang2024phospholipased3regulates pages 10-12, wang2024phospholipased3regulates pages 24-27, wang2024phospholipased3regulates pages 27-30, hoffmann2025ampylationregulatespld3 pages 1-3, hoffmann2025ampylationregulatespld3 pages 26-27).

References (URLs and dates)
- Structural/mechanistic nucleases: Structure (Jun 2024) https://doi.org/10.1016/j.str.2024.02.019 (yuan2024structuralandmechanistic pages 14-17); Nucleic Acids Research (online Nov 22, 2023; 2024) https://doi.org/10.1093/nar/gkad1114 (roske2024structuralanalysisof pages 1-2).
- Enzymology assays: Journal of Biological Chemistry (Jan 2021) https://doi.org/10.1074/jbc.ra120.015867 (cappel2021quantificationandcharacterization pages 6-7, cappel2021quantificationandcharacterization pages 1-2).
- Lysosomal lipid biology/BMP: Cell (Nov 2024) https://doi.org/10.1016/j.cell.2024.09.036 (singh2024pld3andpld4 pages 7-8).
- Nucleotide signaling/APP‑CTF/cholesterol: Nature Communications (May 2023) https://doi.org/10.1038/s41467-023-38501-w (acker2023phospholipased3degrades pages 9-12).
- Neuronal localization/AD neuropathology: PLoS Genetics (preprint, Aug 2021) https://doi.org/10.1101/746222 (nackenoff2021pld3isa pages 4-6).
- Axonal spheroids and network physiology: Nature (Nov 2022) https://doi.org/10.1038/s41586-022-05491-6 (yuan2022pld3affectsaxonal pages 1-2).
- TFEB/TFE3 regulation (preprint): bioRxiv (Sep 2024) https://doi.org/10.1101/2024.09.26.615214 (wang2024phospholipased3regulates pages 1-4, wang2024phospholipased3regulates pages 4-7, wang2024phospholipased3regulates pages 10-12, wang2024phospholipased3regulates pages 24-27, wang2024phospholipased3regulates pages 27-30).
- AMPylation and processing (preprint): bioRxiv (Jan 2025) https://doi.org/10.1101/2025.01.09.632087 (hoffmann2025ampylationregulatespld3 pages 1-3, hoffmann2025ampylationregulatespld3 pages 26-27).

References

1. (roske2024structuralanalysisof pages 1-2): Yvette Roske, Cedric Cappel, Nils Cremer, Patrick Hoffmann, Tomas Koudelka, Andreas Tholey, Udo Heinemann, Oliver Daumke, and Markus Damme. Structural analysis of pld3 reveals insights into the mechanism of lysosomal 5′ exonuclease-mediated nucleic acid degradation. Nucleic Acids Research, 52:370-384, Nov 2024. URL: https://doi.org/10.1093/nar/gkad1114, doi:10.1093/nar/gkad1114. This article has 16 citations and is from a highest quality peer-reviewed journal.

2. (yuan2024structuralandmechanistic pages 14-17): Meng Yuan, Linghang Peng, Deli Huang, Amanda Gavin, Fangkun Luan, Jenny Tran, Ziqi Feng, Xueyong Zhu, Jeanne Matteson, Ian A. Wilson, and David Nemazee. Structural and mechanistic insights into disease-associated endolysosomal exonucleases pld3 and pld4. Structure, 32:766-779.e7, Jun 2024. URL: https://doi.org/10.1016/j.str.2024.02.019, doi:10.1016/j.str.2024.02.019. This article has 11 citations and is from a domain leading peer-reviewed journal.

3. (cappel2021quantificationandcharacterization pages 1-2): Cedric Cappel, Adriana Carolina Gonzalez, and Markus Damme. Quantification and characterization of the 5′ exonuclease activity of the lysosomal nuclease pld3 by a novel cell-based assay. Journal of Biological Chemistry, 296:100152, Jan 2021. URL: https://doi.org/10.1074/jbc.ra120.015867, doi:10.1074/jbc.ra120.015867. This article has 25 citations and is from a domain leading peer-reviewed journal.

4. (singh2024pld3andpld4 pages 7-8): Shubham Singh, Ulrich E. Dransfeld, Yohannes A. Ambaw, Joshua Lopez-Scarim, Robert V. Farese, and Tobias C. Walther. Pld3 and pld4 synthesize s,s-bmp, a key phospholipid enabling lipid degradation in lysosomes. Cell, 187:6820-6834.e24, Nov 2024. URL: https://doi.org/10.1016/j.cell.2024.09.036, doi:10.1016/j.cell.2024.09.036. This article has 37 citations and is from a highest quality peer-reviewed journal.

5. (hoffmann2025ampylationregulatespld3 pages 1-3): Laura Hoffmann, Eva-Maria Eckl, Marleen Bérouti, Michael Pries, Aron Koller, Charlotte Guhl, Ute A. Hellmich, Veit Hornung, Wei Xiang, Lucas T. Jae, and Pavel Kielkowski. Ampylation regulates pld3 processing. bioRxiv, Jan 2025. URL: https://doi.org/10.1101/2025.01.09.632087, doi:10.1101/2025.01.09.632087. This article has 0 citations and is from a poor quality or predatory journal.

6. (hoffmann2025ampylationregulatespld3 pages 26-27): Laura Hoffmann, Eva-Maria Eckl, Marleen Bérouti, Michael Pries, Aron Koller, Charlotte Guhl, Ute A. Hellmich, Veit Hornung, Wei Xiang, Lucas T. Jae, and Pavel Kielkowski. Ampylation regulates pld3 processing. bioRxiv, Jan 2025. URL: https://doi.org/10.1101/2025.01.09.632087, doi:10.1101/2025.01.09.632087. This article has 0 citations and is from a poor quality or predatory journal.

7. (cappel2021quantificationandcharacterization pages 6-7): Cedric Cappel, Adriana Carolina Gonzalez, and Markus Damme. Quantification and characterization of the 5′ exonuclease activity of the lysosomal nuclease pld3 by a novel cell-based assay. Journal of Biological Chemistry, 296:100152, Jan 2021. URL: https://doi.org/10.1074/jbc.ra120.015867, doi:10.1074/jbc.ra120.015867. This article has 25 citations and is from a domain leading peer-reviewed journal.

8. (acker2023phospholipased3degrades pages 9-12): Zoë P. Van Acker, Anika Perdok, Ruben Hellemans, Katherine North, Inge Vorsters, Cedric Cappel, Jonas Dehairs, Johannes V. Swinnen, Ragna Sannerud, Marine Bretou, Markus Damme, and Wim Annaert. Phospholipase d3 degrades mitochondrial dna to regulate nucleotide signaling and app metabolism. Nature Communications, May 2023. URL: https://doi.org/10.1038/s41467-023-38501-w, doi:10.1038/s41467-023-38501-w. This article has 63 citations and is from a highest quality peer-reviewed journal.

9. (nackenoff2021pld3isa pages 4-6): Alex G. Nackenoff, Timothy J. Hohman, Sarah M. Neuner, Carolyn S. Akers, Nicole C. Weitzel, Alena Shostak, Shawn Ferguson, David A. Bennett, Julie A. Schneider, Angela L. Jefferson, Catherine C. Kaczorowski, and Matthew S. Schrag. Pld3 is a neuronal lysosomal phospholipase d associated with β-amyloid plaques and cognitive function in alzheimer’s disease. PLoS Genetics, Aug 2021. URL: https://doi.org/10.1101/746222, doi:10.1101/746222. This article has 52 citations and is from a domain leading peer-reviewed journal.

10. (wang2024phospholipased3regulates pages 1-4): Yongchao Wang, Paige Rieschick, Wilber Romero-Fernandez, Nathan Appelbaum, Cristian Carvajal-Tapia, Alena Shostak, and Matthew Schrag. Phospholipase d3 regulates tfeb/tfe3 metabolism to maintain lysosomal homeostasis. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.26.615214, doi:10.1101/2024.09.26.615214. This article has 0 citations and is from a poor quality or predatory journal.

11. (wang2024phospholipased3regulates pages 4-7): Yongchao Wang, Paige Rieschick, Wilber Romero-Fernandez, Nathan Appelbaum, Cristian Carvajal-Tapia, Alena Shostak, and Matthew Schrag. Phospholipase d3 regulates tfeb/tfe3 metabolism to maintain lysosomal homeostasis. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.26.615214, doi:10.1101/2024.09.26.615214. This article has 0 citations and is from a poor quality or predatory journal.

12. (wang2024phospholipased3regulates pages 10-12): Yongchao Wang, Paige Rieschick, Wilber Romero-Fernandez, Nathan Appelbaum, Cristian Carvajal-Tapia, Alena Shostak, and Matthew Schrag. Phospholipase d3 regulates tfeb/tfe3 metabolism to maintain lysosomal homeostasis. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.26.615214, doi:10.1101/2024.09.26.615214. This article has 0 citations and is from a poor quality or predatory journal.

13. (wang2024phospholipased3regulates pages 24-27): Yongchao Wang, Paige Rieschick, Wilber Romero-Fernandez, Nathan Appelbaum, Cristian Carvajal-Tapia, Alena Shostak, and Matthew Schrag. Phospholipase d3 regulates tfeb/tfe3 metabolism to maintain lysosomal homeostasis. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.26.615214, doi:10.1101/2024.09.26.615214. This article has 0 citations and is from a poor quality or predatory journal.

14. (wang2024phospholipased3regulates pages 27-30): Yongchao Wang, Paige Rieschick, Wilber Romero-Fernandez, Nathan Appelbaum, Cristian Carvajal-Tapia, Alena Shostak, and Matthew Schrag. Phospholipase d3 regulates tfeb/tfe3 metabolism to maintain lysosomal homeostasis. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.26.615214, doi:10.1101/2024.09.26.615214. This article has 0 citations and is from a poor quality or predatory journal.

15. (yuan2022pld3affectsaxonal pages 1-2): Peng Yuan, Mengyang Zhang, Lei Tong, Thomas M. Morse, Robert A. McDougal, Hui Ding, Diane Chan, Yifei Cai, and Jaime Grutzendler. Pld3 affects axonal spheroids and network defects in alzheimer’s disease. Nature, 612:328-337, Nov 2022. URL: https://doi.org/10.1038/s41586-022-05491-6, doi:10.1038/s41586-022-05491-6. This article has 131 citations and is from a highest quality peer-reviewed journal.

## Citations

1. roske2024structuralanalysisof pages 1-2
2. yuan2024structuralandmechanistic pages 14-17
3. cappel2021quantificationandcharacterization pages 1-2
4. cappel2021quantificationandcharacterization pages 6-7
5. https://doi.org/10.1093/nar/gkad1114
6. https://doi.org/10.1016/j.str.2024.02.019
7. https://doi.org/10.1074/jbc.ra120.015867;
8. https://doi.org/10.1016/j.cell.2024.09.036
9. https://doi.org/10.1101/2025.01.09.632087
10. https://doi.org/10.1074/jbc.ra120.015867
11. https://doi.org/10.1038/s41467-023-38501-w
12. https://doi.org/10.1101/746222
13. https://doi.org/10.1093/nar/gkad1114;
14. https://doi.org/10.1101/2024.09.26.615214
15. https://doi.org/10.1016/j.str.2024.02.019;
16. https://doi.org/10.1038/s41586-022-05491-6
17. https://doi.org/10.1093/nar/gkad1114,
18. https://doi.org/10.1016/j.str.2024.02.019,
19. https://doi.org/10.1074/jbc.ra120.015867,
20. https://doi.org/10.1016/j.cell.2024.09.036,
21. https://doi.org/10.1101/2025.01.09.632087,
22. https://doi.org/10.1038/s41467-023-38501-w,
23. https://doi.org/10.1101/746222,
24. https://doi.org/10.1101/2024.09.26.615214,
25. https://doi.org/10.1038/s41586-022-05491-6,